2025-523847-36-00招募中1 期
A Single-Dose Pharmacokinetic Study of Eloralintide in Participants with Varying Degrees of Liver Impairment and Participants with Normal Liver Function
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 12
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Lilly Clinical Trials information desk
Scientific
Eli Lilly & Co.
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal FunctionKidney Failure, ChronicKidney DiseaseRenal InsufficiencyNCT07426380Eli Lilly and Company28
招募中
3 期
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinObesityNCT07392190Eli Lilly and Company900
招募中
3 期
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 DiabetesOverweightObesityObesityNCT07282600Eli Lilly and Company1,035
招募中
1 期
A Phase I trial to investigate the pharmacokinetics and ECG effects of single doses of linaprazan glurate administered as oral tablets to healthy participants2024-516261-36-00Cinclus Pharma Holding AB (publ)113
招募中
1 期
Pharmacokinetics of Olverembatinib in Participants With Hepatic ImpairmentNCT07282093Ascentage Pharma Group Inc.48